Skip to main content

Saxenda FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 28, 2021.

FDA Approved: Yes (First approved December 23, 2014)
Brand name: Saxenda
Generic name: liraglutide
Dosage form: Injection
Company: Novo Nordisk
Treatment for: Obesity

Saxenda (liraglutide) is a once-daily glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity.

Development timeline for Saxenda

Dec  4, 2020Approval FDA Approves Saxenda (liraglutide) for the Treatment of Obesity in Adolescents Aged 12-17
Dec 23, 2014Approval FDA Approves Saxenda (liraglutide [rDNA origin] injection) for Obesity
Sep 11, 2014FDA Advisory Committee Votes 14-1 in Favor of Saxenda (liraglutide) for Obesity

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.